Loading...
Karyopharm Therapeutics Inc.
KPTI•NASDAQ
Healthcare
Biotechnology
$4.55
$-0.45(-9.00%)
Karyopharm Therapeutics Inc. (KPTI) Financial Performance & Statements
Review Karyopharm Therapeutics Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
-0.55%
↓ 0.55%
Operating Income Growth
7.79%
↑ 7.79%
Net Income Growth
46.60%
↑ 46.60%
Operating Cash Flow Growth
-37.49%
↓ 37.49%
Operating Margin
-83.69%
↓ 83.69%
Gross Margin
96.14%
↑ 96.14%
Net Profit Margin
-43.99%
↓ 43.99%
ROE
36.58%
↑ 36.58%
ROIC
-318.52%
↓ 318.52%
Karyopharm Therapeutics Inc. (KPTI) Financial Statements
Explore quarterly and annual reports for Karyopharm Therapeutics Inc. stock.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $30.54M | $38.78M | $42.79M | $33.13M |
| Cost of Revenue | $1.33M | $1.30M | $1.56M | $2.00M |
| Gross Profit | $29.21M | $37.48M | $41.23M | $31.13M |
| Gross Profit Ratio | $0.96 | $0.97 | $0.96 | $0.94 |
| R&D Expenses | $33.30M | $36.13M | $38.28M | $35.34M |
| SG&A Expenses | $27.19M | $27.63M | $31.07M | $29.55M |
| Operating Expenses | $60.49M | $63.77M | $69.35M | $64.89M |
| Total Costs & Expenses | $61.82M | $65.07M | $70.91M | $66.89M |
| Interest Income | $1.48M | $1.83M | $1.93M | $2.16M |
| Interest Expense | $11.20M | $11.38M | $8.95M | $5.88M |
| Depreciation & Amortization | $81000.00 | $83000.00 | $91000.00 | $85000.00 |
| EBITDA | -$19.60M | -$20.58M | $32.90M | -$31.32M |
| EBITDA Ratio | -$0.64 | -$0.53 | $0.77 | -$0.95 |
| Operating Income | -$31.28M | -$26.28M | -$28.12M | -$33.76M |
| Operating Income Ratio | -$1.02 | -$0.68 | -$0.66 | -$1.02 |
| Other Income/Expenses (Net) | $392000.00 | -$5.76M | $51.98M | -$3.53M |
| Income Before Tax | -$30.89M | -$32.04M | $23.86M | -$37.29M |
| Income Before Tax Ratio | -$1.01 | -$0.83 | $0.56 | -$1.13 |
| Income Tax Expense | -$109000.00 | $28000.00 | $67000.00 | $71000.00 |
| Net Income | -$30.78M | -$32.07M | $23.79M | -$37.36M |
| Net Income Ratio | -$1.008 | -$0.83 | $0.56 | -$1.13 |
| EPS | $0.09 | -$0.26 | $0.20 | -$0.32 |
| Diluted EPS | $0.09 | -$0.26 | -$0.20 | -$0.32 |
| Weighted Avg Shares Outstanding | $8.39M | $125.01M | $121.03M | $115.45M |
| Weighted Avg Shares Outstanding (Diluted) | $8.39M | $125.01M | $154.43M | $115.45M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan